Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure

John O. Ike, Fernando Custodio Fervenza, Andrew R. Hoffman, Isabella Yeh, Raymond L. Hintz, Frances Liu, Ralph Rabkin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Short-term high-dose insulin-like growth factor-1 (IGF-1) therapy has been shown to enhance glomerular filtration rate (GFR) in end-stage chronic renal failure (CRF), but the efficacy and safety of prolonged therapy is unproven. To determine if prolonged therapy with IGF-1 can enhance renal function in advanced CRF, eight patients were entered into a study to receive one month of IGF-1 treatment, 60 μg/kg subcutaneously b.i.d. Six patients completed the study and two dropped out for reasons considered to be unrelated to the IGF-1 treatment. Baseline inulin and PAH clearances averaged 17 ± 3 and 66 ± 14 ml/min/1.73 m2, respectively, in the subjects who completed the study. With treatment there was a modest 14% increase in the average GFR which approached statistical significance (P = 0.051). After stopping treatment the clearance values returned to basal values. The PAH clearance showed a similar trend. There were no significant changes in BUN, serum creatinine or electrolyte levels. On the other hand there were marked changes in the serum IGF binding protein (IGFBP) profile. Serum IGFBP-3 levels fell while IGFBP-1 and -2 levels rose during treatment, changes that likely affect the bioavailability of IGF-I. Thus, in this small series of patients IGF-1 treatment produced significant changes in the serum IGFBP profile and a modest upward trend in the GFR.

Original languageEnglish (US)
Pages (from-to)840-849
Number of pages10
JournalKidney International
Volume51
Issue number3
StatePublished - 1997
Externally publishedYes

Fingerprint

Somatomedins
Chronic Kidney Failure
Glomerular Filtration Rate
Blood Proteins
Insulin-Like Growth Factor Binding Proteins
Therapeutics
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 3
Inulin
Blood Urea Nitrogen
Insulin-Like Growth Factor I
Electrolytes
Biological Availability
Creatinine
Kidney
Safety
Serum

ASJC Scopus subject areas

  • Nephrology

Cite this

Ike, J. O., Fervenza, F. C., Hoffman, A. R., Yeh, I., Hintz, R. L., Liu, F., & Rabkin, R. (1997). Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure. Kidney International, 51(3), 840-849.

Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure. / Ike, John O.; Fervenza, Fernando Custodio; Hoffman, Andrew R.; Yeh, Isabella; Hintz, Raymond L.; Liu, Frances; Rabkin, Ralph.

In: Kidney International, Vol. 51, No. 3, 1997, p. 840-849.

Research output: Contribution to journalArticle

Ike, JO, Fervenza, FC, Hoffman, AR, Yeh, I, Hintz, RL, Liu, F & Rabkin, R 1997, 'Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure', Kidney International, vol. 51, no. 3, pp. 840-849.
Ike, John O. ; Fervenza, Fernando Custodio ; Hoffman, Andrew R. ; Yeh, Isabella ; Hintz, Raymond L. ; Liu, Frances ; Rabkin, Ralph. / Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure. In: Kidney International. 1997 ; Vol. 51, No. 3. pp. 840-849.
@article{94dd5bacbe744ad5969ff3229de078e8,
title = "Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure",
abstract = "Short-term high-dose insulin-like growth factor-1 (IGF-1) therapy has been shown to enhance glomerular filtration rate (GFR) in end-stage chronic renal failure (CRF), but the efficacy and safety of prolonged therapy is unproven. To determine if prolonged therapy with IGF-1 can enhance renal function in advanced CRF, eight patients were entered into a study to receive one month of IGF-1 treatment, 60 μg/kg subcutaneously b.i.d. Six patients completed the study and two dropped out for reasons considered to be unrelated to the IGF-1 treatment. Baseline inulin and PAH clearances averaged 17 ± 3 and 66 ± 14 ml/min/1.73 m2, respectively, in the subjects who completed the study. With treatment there was a modest 14{\%} increase in the average GFR which approached statistical significance (P = 0.051). After stopping treatment the clearance values returned to basal values. The PAH clearance showed a similar trend. There were no significant changes in BUN, serum creatinine or electrolyte levels. On the other hand there were marked changes in the serum IGF binding protein (IGFBP) profile. Serum IGFBP-3 levels fell while IGFBP-1 and -2 levels rose during treatment, changes that likely affect the bioavailability of IGF-I. Thus, in this small series of patients IGF-1 treatment produced significant changes in the serum IGFBP profile and a modest upward trend in the GFR.",
author = "Ike, {John O.} and Fervenza, {Fernando Custodio} and Hoffman, {Andrew R.} and Isabella Yeh and Hintz, {Raymond L.} and Frances Liu and Ralph Rabkin",
year = "1997",
language = "English (US)",
volume = "51",
pages = "840--849",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure

AU - Ike, John O.

AU - Fervenza, Fernando Custodio

AU - Hoffman, Andrew R.

AU - Yeh, Isabella

AU - Hintz, Raymond L.

AU - Liu, Frances

AU - Rabkin, Ralph

PY - 1997

Y1 - 1997

N2 - Short-term high-dose insulin-like growth factor-1 (IGF-1) therapy has been shown to enhance glomerular filtration rate (GFR) in end-stage chronic renal failure (CRF), but the efficacy and safety of prolonged therapy is unproven. To determine if prolonged therapy with IGF-1 can enhance renal function in advanced CRF, eight patients were entered into a study to receive one month of IGF-1 treatment, 60 μg/kg subcutaneously b.i.d. Six patients completed the study and two dropped out for reasons considered to be unrelated to the IGF-1 treatment. Baseline inulin and PAH clearances averaged 17 ± 3 and 66 ± 14 ml/min/1.73 m2, respectively, in the subjects who completed the study. With treatment there was a modest 14% increase in the average GFR which approached statistical significance (P = 0.051). After stopping treatment the clearance values returned to basal values. The PAH clearance showed a similar trend. There were no significant changes in BUN, serum creatinine or electrolyte levels. On the other hand there were marked changes in the serum IGF binding protein (IGFBP) profile. Serum IGFBP-3 levels fell while IGFBP-1 and -2 levels rose during treatment, changes that likely affect the bioavailability of IGF-I. Thus, in this small series of patients IGF-1 treatment produced significant changes in the serum IGFBP profile and a modest upward trend in the GFR.

AB - Short-term high-dose insulin-like growth factor-1 (IGF-1) therapy has been shown to enhance glomerular filtration rate (GFR) in end-stage chronic renal failure (CRF), but the efficacy and safety of prolonged therapy is unproven. To determine if prolonged therapy with IGF-1 can enhance renal function in advanced CRF, eight patients were entered into a study to receive one month of IGF-1 treatment, 60 μg/kg subcutaneously b.i.d. Six patients completed the study and two dropped out for reasons considered to be unrelated to the IGF-1 treatment. Baseline inulin and PAH clearances averaged 17 ± 3 and 66 ± 14 ml/min/1.73 m2, respectively, in the subjects who completed the study. With treatment there was a modest 14% increase in the average GFR which approached statistical significance (P = 0.051). After stopping treatment the clearance values returned to basal values. The PAH clearance showed a similar trend. There were no significant changes in BUN, serum creatinine or electrolyte levels. On the other hand there were marked changes in the serum IGF binding protein (IGFBP) profile. Serum IGFBP-3 levels fell while IGFBP-1 and -2 levels rose during treatment, changes that likely affect the bioavailability of IGF-I. Thus, in this small series of patients IGF-1 treatment produced significant changes in the serum IGFBP profile and a modest upward trend in the GFR.

UR - http://www.scopus.com/inward/record.url?scp=0030988920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030988920&partnerID=8YFLogxK

M3 - Article

C2 - 9067919

AN - SCOPUS:0030988920

VL - 51

SP - 840

EP - 849

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -